{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:54:46Z","timestamp":1792364086667,"version":"4.4.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.autrev.2023.103464","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:14:15Z","timestamp":1697674455000},"page":"103464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review"],"prefix":"10.1016","volume":"22","author":[{"given":"Ozgur C.","family":"Kilinc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdal","family":"Ugurlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103464_bb0005","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1212\/01.CON.0000511070.50715.ab","article-title":"Autoimmune myopathies","volume":"22","author":"Mammen","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"10019","key":"10.1016\/j.autrev.2023.103464_bb0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103464_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084301","article-title":"Pathophysiological mechanisms and treatment of dermatomyositis and immune mediated necrotizing myopathies: a focused review","volume":"23","author":"Kamperman","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"40","author":"Long","year":"2019","journal-title":"Clin Chest Med"},{"issue":"5","key":"10.1016\/j.autrev.2023.103464_bb0040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/WCO.0000000000001091","article-title":"Update on dermatomyositis","volume":"35","author":"Tanboon","year":"2022","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/ds.DS-D-22-00122","article-title":"Myositis-specific antibodies in dermatomyositis: a single-center experience of 33 cases in Taiwan","volume":"41","author":"Liu","year":"2023","journal-title":"Dermatol Sin"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150201","article-title":"Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence","volume":"132","author":"Fiorentino","year":"2022","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.autrev.2023.103464_bb0055","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/jcla.21948","article-title":"A new immunodot assay for multiplex detection of autoantibodies in a cohort of Italian patients with idiopathic inflammatory myopathies","volume":"30","author":"Tampoia","year":"2016","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.autrev.2023.103464_bb0060","article-title":"Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population","volume":"9","author":"Hormaza-Jaramillo","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0065","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/art.42311","article-title":"Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population","volume":"75","author":"Mecoli","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103464_bb0070","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1093\/rheumatology\/keaa112","article-title":"Clinically amyopathic dermatomyositis with anti-transcriptional intermediary factor 1-gamma autoantibody positivity","volume":"59","author":"Kanaoka","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0075","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.autrev.2023.103464_bb0085","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s10067-019-04503-7","article-title":"The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103464_bb0090","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1111\/1756-185X.14773","article-title":"Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis","volume":"26","author":"Gezgin Yildirim","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0095","first-page":"195","article-title":"Geng yin the clinical significance of tumor-associated antigens in dermatomyositis patients with interstitial lung disease","volume":"49","author":"Yuan Yang","year":"2018","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"issue":"13","key":"10.1016\/j.autrev.2023.103464_bb0100","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/1759-7714.14849","article-title":"Clinical features and risk factors of lung cancer in elderly patients with dermatomyositis","volume":"14","author":"Zhou","year":"2023","journal-title":"Thorac Cancer"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0105","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/rheumatology\/keaa429","article-title":"Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America","volume":"60","author":"Mamyrova","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2023.103464_bb0110","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1346-8138.2011.01262.x","article-title":"Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients","volume":"38","author":"Ikeda","year":"2011","journal-title":"J Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103464_bb0115","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/art.40895","article-title":"The IgG2 isotype of anti-transcription intermediary factor 1gamma autoantibodies is a biomarker of cancer and mortality in adult dermatomyositis","volume":"71","author":"Aussy","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0120","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","article-title":"Clinical associations of autoantibodies to a p155\/140 kDa doublet protein in juvenile dermatomyositis","volume":"47","author":"Gunawardena","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2023.103464_bb0130","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103464_bb0140","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0145","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/jdv.12591","article-title":"Autoantibodies against TIF-1-gamma and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility","volume":"29","author":"Cuesta-Mateos","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12957","article-title":"NanoString technology distinguishes anti-TIF-1gamma(+) from anti-Mi-2(+) dermatomyositis patients","volume":"31","author":"Preusse","year":"2021","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/1756-185X.14046","article-title":"Risk factors for cancer-associated myositis: a large-scale multicenter cohort study","volume":"24","author":"Li","year":"2021","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2023.103464_bb0165","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.17219\/acem\/141181","article-title":"Characteristics of idiopathic inflammatory myopathies with novel myositis-specific autoantibodies","volume":"30","author":"Rams","year":"2021","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/24725625.2017.1380874","article-title":"Effectiveness of IVIG and balloon dilation combination therapy for refractory dysphagia in anti-TIF1-\u03b3 antibody-positive dermatomyositis","volume":"2","author":"Akira Utsunomiya","year":"2018","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0175","doi-asserted-by":"crossref","DOI":"10.5070\/D329260773","article-title":"Amyopathic dermatomyositis with TIF1? Positivity treated with IVIG","volume":"29","author":"Jiang","year":"2023","journal-title":"Dermatol Online J"},{"issue":"11","key":"10.1016\/j.autrev.2023.103464_bb0180","doi-asserted-by":"crossref","first-page":"768","DOI":"10.5692\/clinicalneurol.cn-001443","article-title":"Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report","volume":"60","author":"Miyashita","year":"2020","journal-title":"Rinsho Shinkeigaku"},{"issue":"7","key":"10.1016\/j.autrev.2023.103464_bb0185","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1111\/jdv.18060","article-title":"Two cases of anti-TIF1-gamma antibody positive dermatomyositis with manifested symptoms after SARS-CoV-19 vaccination","volume":"36","author":"Yoshida","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103464_bb0190","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/1346-8138.13579","article-title":"Case of anti-transcriptional intermediary factor-1-positive dermatomyositis associated with breast cancer developing over 10 years","volume":"44","author":"Matsushita","year":"2017","journal-title":"J Dermatol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103464_bb0195","first-page":"1866","article-title":"The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease","volume":"57","author":"Rodziewicz","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2023.103464_bb0200","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/17843286.2023.2183577","article-title":"Systemic autoimmune rheumatic diseases as paraneoplastic phenomena: 3 illustrative case reports and narrative review of the literature","volume":"78","author":"Poelman","year":"2023","journal-title":"Acta Clin Belg"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0205","first-page":"253","article-title":"Paraneoplastic anti-Tif1-gamma autoantibody-positive dermatomyositis as clinical presentation of hepatocellular carcinoma recurrence","volume":"11","author":"Ferronato","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.autrev.2023.103464_bb0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13569-020-00140-w","article-title":"Paraneoplastic dermatomyositis associated with metastatic leiomyosarcoma of unknown primary","volume":"10","author":"Merry","year":"2020","journal-title":"Clin Sarcoma Res"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0215","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/24725625.2020.1789302","article-title":"Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site","volume":"5","author":"Hori","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.autrev.2023.103464_bb0220","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jdcr.2022.05.018","article-title":"Multiple myositis-specific autoantibodies in dermatomyositis: 2 cases and review of the literature","volume":"25","author":"Narayan","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0225","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13256-019-2105-9","article-title":"Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report","volume":"13","author":"Shibata","year":"2019","journal-title":"J Med Case Reports"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0230","article-title":"Marked improvement of anti-TIF1-gamma antibody-positive dermatomyositis after chemoradiotherapy to relevant nasopharyngeal cancer","volume":"6","author":"Tomita","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103464_bb0235","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/ijd.16358","article-title":"Manifestation of a cancer-associated TIF-1 gamma dermatomyositis after COVID-19 vaccine","volume":"61","author":"Ooi","year":"2022","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.403","article-title":"Lung adenocarcinoma and anti-transcriptional intermediary factor 1-gamma positive dermatomyositis complicated with spontaneous oesophageal rupture","volume":"7","author":"Saraya","year":"2019","journal-title":"Respirol Case Rep"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0245","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/rheumatology\/kex342","article-title":"Anti-TIF1-gamma autoantibodies-positive dermatomyositis: where is the malignancy?","volume":"57","author":"Zachou","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2023.103464_bb0250","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/ddg.14915","article-title":"Wong-type dermatomyositis associated with parotid gland tumor and anti-TIF1-gamma antibody","volume":"20","author":"Xue","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4081\/reumatismo.2017.923","article-title":"First report of anti-TIF1gamma dermatomyositis in a patient with myelodysplastic syndrome","volume":"69","author":"Palterer","year":"2017","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2023.103464_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227574","article-title":"Dermatomyositis with anti-TIF1-gamma antibodies","volume":"2018","author":"De Greef","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0265","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12890-022-01974-4","article-title":"Development of dermatomyositis after anti-transcriptional intermediary factor 1-gamma antibody seroconversion during treatment for small cell lung cancer","volume":"22","author":"Sato","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0270","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10067-020-05424-6","article-title":"Cutaneous features of anti-TIF1-gamma-associated dermatomyositis","volume":"40","author":"Ho","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0275","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2169\/internalmedicine.7924-21","article-title":"Clinical and serological features and pregnancy outcomes in women with polymyositis\/dermatomyositis: a case-based review","volume":"61","author":"Ito","year":"2022","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0280","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2169\/internalmedicine.7995-21","article-title":"Cancer-associated dermatomyositis with histiocytic sarcoma","volume":"61","author":"Tsutsumi","year":"2022","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0285","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1111\/ajd.13232","article-title":"The clinical spectrum of dermatomyositis and the new autoantibodies - with regard to two clinical cases with distinct associations","volume":"61","author":"Calvao da Silva","year":"2020","journal-title":"Australas J Dermatol"},{"issue":"18","key":"10.1016\/j.autrev.2023.103464_bb0290","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2169\/internalmedicine.6917-20","article-title":"Atezolizumab-associated dermatomyositis in advanced small-cell lung carcinoma","volume":"60","author":"Yamaguchi","year":"2021","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0295","first-page":"395","article-title":"Anti-TIF1-gamma antibody-positive dermatomyositis caused by camrelizumab in a patient with oesophageal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0300","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10637-020-00974-7","article-title":"Anti-transcriptional intermediary factor 1-gamma antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: a case report","volume":"39","author":"Osaki","year":"2021","journal-title":"Invest New Drugs"},{"issue":"49","key":"10.1016\/j.autrev.2023.103464_bb0305","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013563","article-title":"Anti-TIF1gamma antibody predicted malignancy of thymic tumor with dermatomyositis as an \u201cautoimmune tumor marker\u201d: a case report","volume":"97","author":"Karino","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0310","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ddg.13394","article-title":"Amyopathic dermatomyositis with anti-TIF1 gamma antibodies","volume":"16","author":"Schiffmann","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0315","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13256-021-02664-1","article-title":"Anti-transcription intermediary factor 1 gamma (TIF1gamma) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature","volume":"15","author":"Ono","year":"2021","journal-title":"J Med Case Reports"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0320","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3390\/curroncol28030182","article-title":"A case of pathological complete response and resolution of dermatomyositis following neoadjuvant chemotherapy in HER2-positive early breast cancer","volume":"28","author":"Piras","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.autrev.2023.103464_bb0325","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.922004","article-title":"A case of dermatomyositis along with esophageal cancer and screening of serum transcriptional intermediary factor 1 gamma antibodies in various cancer patients","volume":"21","author":"Sumazaki","year":"2020","journal-title":"Am J Case Rep"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0330","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2169\/internalmedicine.1007-18","article-title":"Small cell lung cancer patient with anti-transcriptional intermediary factor 1gamma antibody who developed dermatomyositis after successful chemoradiotherapy","volume":"58","author":"Aritomi","year":"2019","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0335","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1620\/tjem.2022.J006","article-title":"Anti-Mi-2 and anti-TIF1-gamma double-positive juvenile dermatomyositis treated under diagnosis of chronic eczema: a case report","volume":"256","author":"Yoshida","year":"2022","journal-title":"Tohoku J Exp Med"},{"issue":"5","key":"10.1016\/j.autrev.2023.103464_bb0340","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3892\/mco.2020.2130","article-title":"An extragonadal germ cell tumor with dermatomyositis: a case report and literature review","volume":"13","author":"Fujiwara","year":"2020","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0345","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/24725625.2020.1826650","article-title":"Rapid changes of nailfold capillary abnormalities during treatment for a patient with dermatomyositis complicated by lung cancer: a case report","volume":"5","author":"Sugimoto","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"issue":"7","key":"10.1016\/j.autrev.2023.103464_bb0350","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/1346-8138.12141","article-title":"Case report of anti-transcription intermediary factor-1-gamma\/alpha antibody-positive dermatomyositis associated with gastric cancer and immunoglobulin G4-positive pulmonary inflammatory pseudotumor","volume":"40","author":"Ito","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2023.103464_bb0355","article-title":"Case report: IgA nephropathy in a patient with anti-transcription intermediary factor-1gamma antibody-positive dermatomyositis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0360","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000368274","article-title":"A case of dermatomyositis with esophageal fistula in whom blind mucosal biopsy detected occult oropharyngeal carcinoma","volume":"6","author":"Kabuto","year":"2014","journal-title":"Case Rep Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.412","article-title":"Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1gamma-positive dermatomyositis","volume":"7","author":"Kato","year":"2019","journal-title":"Respirol Case Rep"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0370","first-page":"75","article-title":"The cancer immunotherapy environment may confound the utility of anti-TIF-1gamma in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature","volume":"24","author":"Zarkavelis","year":"2020","journal-title":"Contemp Oncol (Pozn)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0375","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12885-016-2715-1","article-title":"Dermatomyositis with anti-TIF-1gamma antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report","volume":"16","author":"Kubecek","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.autrev.2023.103464_bb0380","first-page":"27(4)","article-title":"Anti-MDA-5 negative, anti-Ku positive clinically amyopathic dermatomyositis","author":"Carrington","year":"2021","journal-title":"Dermatol Online J"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0385","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/CND.0000000000000378","article-title":"Anti-TIF-1alpha\/gamma antibody-positive dermatomyositis associated with metastatic prostatic adenocarcinoma","volume":"23","author":"Psomadakis","year":"2021","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103464_bb0390","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3109\/14397595.2014.896494","article-title":"Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients","volume":"24","author":"Kang","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0395","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/bjd.17098","article-title":"Autoantibody to transcriptional intermediary factor-1beta as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy","volume":"180","author":"Ueda-Hayakawa","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0400","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14397595.2018.1452353","article-title":"Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies","volume":"29","author":"Ueki","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0405","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1346-8138.15128","article-title":"Anti-transcriptional intermediary factor 1-gamma antibody as a biomarker in patients with dermatomyositis","volume":"47","author":"Shimizu","year":"2020","journal-title":"J Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103464_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11071925","article-title":"Clinical characteristics of anti-TIF-1gamma antibody-positive dermatomyositis associated with malignancy","volume":"11","author":"Harada","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0415","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1684\/ejd.2020.3766","article-title":"Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria","volume":"30","author":"Didona","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103464_bb0420","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/annrheumdis-2011-200871","article-title":"Anti-TIF1gamma antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays","volume":"71","author":"Labrador-Horrillo","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2023.103464_bb0425","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/1346-8138.15049","article-title":"Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies","volume":"46","author":"Fukamatsu","year":"2019","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0430","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar3802","article-title":"Autoantibodies to transcription intermediary factor TIF1beta associated with dermatomyositis","volume":"14","author":"Satoh","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0435","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2340\/00015555-3091","article-title":"Use of anti-transcriptional intermediary Factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis","volume":"99","author":"Best","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0440","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40257-015-0120-1","article-title":"Cancer risk in dermatomyositis: a meta-analysis of cohort studies","volume":"16","author":"Olazagasti","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0445","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjd.12564","article-title":"Meta-analysis of the association of dermatomyositis and polymyositis with cancer","volume":"169","author":"Wang","year":"2013","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094128","article-title":"Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis","volume":"9","author":"Lu","year":"2014","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.autrev.2023.103464_bb0455","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: a metaanalysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0460","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020","volume":"51","author":"Sun","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2023.103464_bb0465","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14572","article-title":"A systematic review and meta-analysis on the prevalence and clinical characteristics of dysphagia in patients with dermatomyositis","volume":"35","author":"Cheng","year":"2023","journal-title":"Neurogastroenterol Motil"},{"issue":"7","key":"10.1016\/j.autrev.2023.103464_bb0470","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1093\/rheumatology\/keab851","article-title":"Cardiovascular events in adult polymyositis and dermatomyositis: a meta-analysis of observational studies","volume":"61","author":"Xiong","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2023.103464_bb0475","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10147-016-0979-8","article-title":"KAP1 is overexpressed in hepatocellular carcinoma and its clinical significance","volume":"21","author":"Wang","year":"2016","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0480","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/ijms16010363","article-title":"High levels of KAP1 expression are associated with aggressive clinical features in ovarian cancer","volume":"16","author":"Cui","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.autrev.2023.103464_bb0485","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12032-014-0025-5","article-title":"KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer","volume":"31","author":"Yu","year":"2014","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0490","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","article-title":"TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance","volume":"8","author":"Ma","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0495","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-021-01399-3","article-title":"RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment","volume":"20","author":"Park","year":"2021","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.autrev.2023.103464_bb0500","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/2326-6066.CIR-21-0754","article-title":"The SETDB1-TRIM28 complex suppresses antitumor immunity","volume":"9","author":"Lin","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"50","key":"10.1016\/j.autrev.2023.103464_bb0505","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1038\/s41388-022-02538-w","article-title":"LncRNA PVT-1 promotes osteosarcoma cancer stem-like properties through direct interaction with TRIM28 and TSC2 ubiquitination","volume":"41","author":"Tsang","year":"2022","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.autrev.2023.103464_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071528","article-title":"The association between TIF1 family members and cancer stemness in solid tumors","volume":"13","author":"Czerwinska","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0515","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"10.1016\/j.autrev.2023.103464_bb0520","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-020-00950-3","article-title":"Impact and management of dysphagia in inflammatory myopathies","volume":"22","author":"Zeng","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"10.1016\/j.autrev.2023.103464_bb0525","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","article-title":"A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies","volume":"54","author":"Gerami","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"6917","key":"10.1016\/j.autrev.2023.103464_bb0530","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0535","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0300-483X(02)00612-1","article-title":"Immunosuppressive drugs and cancer","volume":"185","author":"Vial","year":"2003","journal-title":"Toxicology"},{"issue":"11","key":"10.1016\/j.autrev.2023.103464_bb0540","doi-asserted-by":"crossref","first-page":"10875","DOI":"10.1007\/s11033-022-07788-1","article-title":"The cell cycle, cancer development and therapy","volume":"49","author":"Jamasbi","year":"2022","journal-title":"Mol Biol Rep"},{"issue":"8","key":"10.1016\/j.autrev.2023.103464_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082094","article-title":"TIF1 proteins in genome stability and cancer","volume":"12","author":"McAvera","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.autrev.2023.103464_bb0550","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.27273","article-title":"Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma","volume":"60","author":"Ding","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111513","article-title":"TIF1gamma inhibits lung adenocarcinoma EMT and metastasis by interacting with the TAF15\/TBP complex","volume":"41","author":"Su","year":"2022","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.autrev.2023.103464_bb0560","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.696","article-title":"KLF9 positively regulates TRIM33 to inhibit abnormal synovial fibroblast proliferation, migration as well as inflammation in rheumatoid arthritis","volume":"10","author":"Huang","year":"2022","journal-title":"Immun Inflamm Dis"},{"issue":"10","key":"10.1016\/j.autrev.2023.103464_bb0565","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1159\/000524574","article-title":"TRIM33 modulates inflammation and airway remodeling of PDGF-BB-induced airway smooth-muscle cells by the Wnt\/beta-catenin pathway","volume":"183","author":"Li","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103464_bb0570","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01346-2019","article-title":"TRIM33 prevents pulmonary fibrosis by impairing TGF-beta1 signalling","volume":"55","author":"Boutanquoi","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.autrev.2023.103464_bb0575","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.20170779","article-title":"Trim33 mediates the proinflammatory function of Th17 cells","volume":"215","author":"Tanaka","year":"2018","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103464_bb0580","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.18632\/oncotarget.13872","article-title":"Macrophage production and activation are dependent on TRIM33","volume":"8","author":"Gallouet","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0585","doi-asserted-by":"crossref","first-page":"121","DOI":"10.23736\/S0026-4806.20.06647-1","article-title":"TRIM33\/RORgammat signaling pathway promoted immune inflammation in mice of AE through miR-338-3p\/Circ RNA 001076","volume":"114","author":"Duan","year":"2023","journal-title":"Minerva Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103464_bb0590","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1128\/JVI.06583-11","article-title":"Adenovirus E4orf3 targets transcriptional intermediary factor 1gamma for proteasome-dependent degradation during infection","volume":"86","author":"Forrester","year":"2012","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103464_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011477","article-title":"Changes in SUMO-modified proteins in Epstein-Barr virus infection identifies reciprocal regulation of TRIM24\/28\/33 complexes and the lytic switch BZLF1","volume":"19","author":"De La Cruz-Herrera","year":"2023","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0600","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41467-019-08810-0","article-title":"Cellular TRIM33 restrains HIV-1 infection by targeting viral integrase for proteasomal degradation","volume":"10","author":"Ali","year":"2019","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.autrev.2023.103464_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/v12091015","article-title":"Trim24 and Trim33 play a role in epigenetic silencing of retroviruses in embryonic stem cells","volume":"12","author":"Margalit","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.autrev.2023.103464_bb0610","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s42003-021-01932-6","article-title":"Analysis of human total antibody repertoires in TIF1gamma autoantibody positive dermatomyositis","volume":"4","author":"Megremis","year":"2021","journal-title":"Commun Biol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:31:39Z","timestamp":1761600699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":122,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1568997223001982"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103464","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103464"}}